Malaysia
Malaysia Epigenetics Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Malaysia · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
China at $186.7 Mn.
India at 16.7% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$7.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $3.1 Mn | — | — |
| 2025 (base) | $3.5 Mn | +$0.4 Mn | — |
| 2026 (forecast) | $4.0 Mn | +$0.5 Mn | +13.9% |
| 2027 (forecast) | $4.5 Mn | +$0.6 Mn | +29.7% |
| 2028 (forecast) | $5.2 Mn | +$0.6 Mn | +47.8% |
| 2029 (forecast) | $5.9 Mn | +$0.7 Mn | +68.3% |
| 2030 (forecast) | $6.7 Mn | +$0.8 Mn | +91.7% |
| 2031 (forecast) | $7.6 Mn | +$0.9 Mn | +118.3% |
| 2032 (forecast) | $8.7 Mn | +$1.1 Mn | +148.7% |
| 2033 (forecast) | $9.9 Mn | +$1.2 Mn | +183.3% |
| 2034 (forecast) | $11.3 Mn | +$1.4 Mn | +222.6% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$911.4 Mn
Canada
$206.1 Mn
China
$186.7 Mn
Japan
$137.3 Mn
Germany
$85.1 Mn
France
$63.1 Mn
UK
$55.8 Mn
Brazil
$57.0 Mn
Italy
$50.8 Mn
Ecuador
$50.3 Mn
Saudi Arabia
$45.7 Mn
Spain
$42.0 Mn
India
$42.9 Mn
Mexico
$37.8 Mn
Russia
$26.3 Mn
Australia
$25.6 Mn
New Zealand
$25.3 Mn
South Africa
$14.4 Mn
UAE
$11.9 Mn
Egypt
$6.1 Mn
Philippines
$5.8 Mn
Malaysia (this report)
$3.5 Mn
Hong Kong
$3.5 Mn
Singapore
$2.8 Mn
Thailand
$2.6 Mn
Kenya
$1.7 Mn
Epigenetics studies chemical marks on DNA that turn genes on and off, used in research, cancer tests and drug discovery.
Key segments of the epigenetics market include product (Reagents, Kits and Instruments) and application (Oncology, Developmental Biology and Metabolic Diseases).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the epigenetics market.
Routine use of genomics in screening, pharmacy and primary care gives the epigenetics market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the epigenetics market.
The epigenetics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for epigenetics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.
What doctors and scientists are doing in Epigenetics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Malaysia · 4 shared keywords
Malaysia · 3 shared keywords
Malaysia · 2 shared keywords
Malaysia · 2 shared keywords
Malaysia · 1 shared keyword
Malaysia · 1 shared keyword
Digital Health · Malaysia
Healthcare Services · Malaysia
Healthcare Services · Malaysia
Medical Devices · Malaysia
Digital Health · Malaysia
Medical Devices · Malaysia